TY  - JOUR
AU  - Eckert, Franziska
AU  - Ganser, Katrin
AU  - Bender, Benjamin
AU  - Schittenhelm, Jens
AU  - Skardelly, Marco
AU  - Behling, Felix
AU  - Tabatabai, Ghazaleh
AU  - Stransky, Nicolai
AU  - Hoffmann, Elgin
AU  - Zips, Daniel
AU  - Huber, Stephan M
AU  - Paulsen, Frank
TI  - Potential of pre-operative MRI features in glioblastoma to predict for molecular stem cell subtype and patient overall survival.
JO  - Radiotherapy and oncology
VL  - 188
SN  - 0167-8140
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2023-01716
SP  - 109865
PY  - 2023
N1  - Volume 188, November 2023, 109865
AB  - of the study. A molecular signature based on 10 mRNA abundances that characterizes the mesenchymal-to-proneural phenotype of glioblastoma stem(like) cells (GSCs) enriched in primary culture has been previously established. As this phenotype has been proposed to be prognostic for disease outcome the present study aims to identify features of the preoperative MR imaging that may predict the GSC phenotype of individual tumors.Molecular mesenchymal-to-proneural mRNA signatures and intrinsic radioresistance (SF4, survival fraction at 4 Gy) of primary GSC-enriched cultures were associated with survival data and pre-operative MR imaging of the corresponding glioblastoma patients of a prospective cohort (n = 24). The analyzed imaging parameters comprised linear vectors derived from tumor volume, necrotic volume and edema as contoured manually.A necrosis/tumor vector ratio and to a weaker extent the product of this ratio and the edema vector were identified to correlate with the mesenchymal-to-proneural mRNA signature and the SF4 of the patient-derived GSC cultures. Importantly, both parameter combinations were predictive for overall survival of the whole patient cohort. Moreover, the combination of necrosis/tumor vector ratio and edema vector differed significantly between uni- and multifocally recurring tumors.Features of the preoperative MR images may reflect the molecular signature of the GSC population and might be used in the future as a prognostic factor and for treatment stratification especially in the MGMT promotor-unmethylated sub-cohort of glioblastoma patients.
KW  - Glioblastoma (Other)
KW  - MGMT promoter methylation (Other)
KW  - MRI (Other)
KW  - mesenchymal (Other)
KW  - proneural (Other)
KW  - stem cells (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37619660
DO  - DOI:10.1016/j.radonc.2023.109865
UR  - https://inrepo02.dkfz.de/record/278806
ER  -